BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
BioHarvest Sciences (NASDAQ: BHST) has successfully completed Stage 1 of its CDMO contract with an unnamed Nasdaq-listed pharmaceutical company and is advancing to Stage 2. The project, which began in early 2024, demonstrates the capability of BioHarvest's Botanical Synthesis platform to develop active pharmaceutical compounds.
In Stage 1, BioHarvest's research team successfully isolated target plant cells and replicated them using their proprietary platform. Stage 2 will focus on producing sufficient biomass for testing and developing optimal growing conditions in liquid media. Upon success, the project will progress to small and medium-scale production before moving to commercial volume production.
This milestone validates the platform's versatility and positions BioHarvest as a trusted partner in providing scalable, cost-effective alternatives to traditional compound sourcing for pharmaceutical, nutrition, and nutraceutical industries.BioHarvest Sciences (NASDAQ: BHST) ha completato con successo la Fase 1 del suo contratto CDMO con una società farmaceutica quotata al Nasdaq, il cui nome rimane riservato, e sta procedendo verso la Fase 2. Il progetto, iniziato all'inizio del 2024, dimostra la capacità della piattaforma Botanical Synthesis di BioHarvest di sviluppare composti farmaceutici attivi.
Durante la Fase 1, il team di ricerca di BioHarvest ha isolato con successo le cellule vegetali target e le ha replicate utilizzando la loro piattaforma proprietaria. La Fase 2 si concentrerà sulla produzione di biomassa sufficiente per i test e lo sviluppo delle condizioni ottimali di crescita in coltura liquida. In caso di successo, il progetto procederà alla produzione su scala piccola e media, prima di passare alla produzione su scala commerciale.
Questo traguardo conferma la versatilità della piattaforma e posiziona BioHarvest come un partner affidabile nell'offrire alternative scalabili e convenienti alle fonti tradizionali di composti per le industrie farmaceutiche, nutrizionali e nutraceutiche.
BioHarvest Sciences (NASDAQ: BHST) ha completado con éxito la Etapa 1 de su contrato CDMO con una compañía farmacéutica listada en Nasdaq, cuyo nombre no ha sido revelado, y avanza hacia la Etapa 2. El proyecto, que comenzó a principios de 2024, demuestra la capacidad de la plataforma Botanical Synthesis de BioHarvest para desarrollar compuestos farmacéuticos activos.
En la Etapa 1, el equipo de investigación de BioHarvest aisló con éxito las células vegetales objetivo y las replicó usando su plataforma propietaria. La Etapa 2 se centrará en producir biomasa suficiente para pruebas y en desarrollar las condiciones óptimas de cultivo en medios líquidos. Tras el éxito, el proyecto avanzará a producción a pequeña y mediana escala antes de pasar a la producción a volumen comercial.
Este logro valida la versatilidad de la plataforma y posiciona a BioHarvest como un socio confiable que ofrece alternativas escalables y rentables a las fuentes tradicionales de compuestos para las industrias farmacéutica, nutricional y nutracéutica.
BioHarvest Sciences (NASDAQ: BHST)는 나스닥 상장 제약사와의 CDMO 계약 1단계를 성공적으로 완료하고 2단계로 진입했습니다. 2024년 초에 시작된 이 프로젝트는 BioHarvest의 Botanical Synthesis 플랫폼이 활성 제약 화합물을 개발할 수 있는 역량을 입증합니다.
1단계에서 BioHarvest 연구팀은 목표 식물 세포를 성공적으로 분리하고 독자적인 플랫폼을 이용해 복제했습니다. 2단계에서는 테스트를 위한 충분한 바이오매스 생산과 액체 배지에서 최적의 성장 조건 개발에 집중할 예정입니다. 성공 시, 프로젝트는 소규모 및 중간 규모 생산으로 진행한 후 상업적 대량 생산으로 확대됩니다.
이번 성과는 플랫폼의 다재다능함을 검증하며, BioHarvest를 제약, 영양 및 뉴트라슈티컬 산업에 전통적인 화합물 공급 방식에 대한 확장 가능하고 비용 효율적인 대안을 제공하는 신뢰받는 파트너로 자리매김하게 합니다.
BioHarvest Sciences (NASDAQ : BHST) a réussi à compléter la première étape de son contrat CDMO avec une entreprise pharmaceutique cotée au Nasdaq, dont le nom reste confidentiel, et passe à l'étape 2. Le projet, lancé début 2024, démontre la capacité de la plateforme Botanical Synthesis de BioHarvest à développer des composés pharmaceutiques actifs.
Lors de l'étape 1, l'équipe de recherche de BioHarvest a isolé avec succès les cellules végétales cibles et les a reproduites grâce à leur plateforme propriétaire. L'étape 2 se concentrera sur la production d'une biomasse suffisante pour les tests et le développement des conditions optimales de culture en milieu liquide. En cas de succès, le projet progressera vers une production à petite et moyenne échelle avant de passer à la production commerciale à grande échelle.
Cette étape clé valide la polyvalence de la plateforme et positionne BioHarvest comme un partenaire de confiance offrant des alternatives évolutives et économiques aux méthodes traditionnelles d'approvisionnement en composés pour les industries pharmaceutiques, nutritionnelles et nutraceutiques.
BioHarvest Sciences (NASDAQ: BHST) hat die erste Phase seines CDMO-Vertrags mit einem nicht genannten, an der Nasdaq gelisteten Pharmaunternehmen erfolgreich abgeschlossen und schreitet zur zweiten Phase voran. Das Projekt, das Anfang 2024 begann, zeigt die Fähigkeit der Botanical Synthesis Plattform von BioHarvest, aktive pharmazeutische Verbindungen zu entwickeln.
In Phase 1 isolierte das Forschungsteam von BioHarvest erfolgreich die Zielpflanzenzellen und replizierte sie mithilfe ihrer proprietären Plattform. Phase 2 konzentriert sich auf die Produktion ausreichender Biomasse für Tests und die Entwicklung optimaler Wachstumsbedingungen in flüssigen Medien. Bei Erfolg wird das Projekt in die Klein- und Mittelserienproduktion übergehen, bevor es in die kommerzielle Massenproduktion geht.
Dieser Meilenstein bestätigt die Vielseitigkeit der Plattform und positioniert BioHarvest als vertrauenswürdigen Partner, der skalierbare und kosteneffiziente Alternativen zur herkömmlichen Beschaffung von Verbindungen für die Pharma-, Ernährungs- und Nutraceutical-Industrie bietet.
- Successfully completed Stage 1 of CDMO contract with a Nasdaq-listed pharmaceutical company
- Platform demonstrates versatility in developing active pharmaceutical compounds
- Project advances to Stage 2 with higher probability of success
- Enhanced analytical capabilities and validated in-house AI tools for future CDMO engagements
- None.
Insights
BioHarvest's successful CDMO contract progression validates their Botanical Synthesis platform while opening revenue opportunities in pharmaceutical manufacturing.
BioHarvest has achieved a significant milestone by completing Stage 1 of their CDMO contract with an unnamed Nasdaq-listed pharmaceutical company. This stage involved the crucial technical challenge of isolating, mirroring, and multiplying specific plant cells using their proprietary Botanical Synthesis platform to develop compounds for an approved drug product. The success here demonstrates the platform's versatility in handling various molecule types, which expands BioHarvest's potential applications across pharmaceuticals and nutraceuticals.
Moving to Stage 2, BioHarvest will now focus on scaling biomass production in liquid media to deliver testable quantities of the target compound. This progression follows a logical development path toward commercial-scale manufacturing. What's particularly noteworthy is that Stage 1 carried the highest technical risk, while Stage 2 has a "much higher probability of success" according to their CDMO Division President. This risk reduction sequence is standard in biotech development but critical for investor confidence.
The company's integration of AI tools for analytics during this project represents an important technological advancement. These tools have now been validated through this process and will support future CDMO engagements, potentially accelerating development timelines and reducing costs. Although financial details weren't disclosed, CDMO contracts typically follow milestone payment structures, suggesting this advancement likely triggers a payment while opening the path to the more lucrative manufacturing phase. This project serves as a proof-of-concept that could attract additional pharmaceutical partners seeking plant-derived compounds.
Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types
Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing.
Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product. Completion of Stage 1 indicates that the BioHarvest research team successfully isolated the cells of the target plant and mirrored, magnified and multiplied those cells in petri dishes using the Company's proprietary Botanical Synthesis platform.
Stage 2 involves the delivery of a sufficient amount of biomass to be tested for suitability and involves the development of optimal growing conditions in liquid media. Upon successful completion, the company would transfer to small and medium-scale production and ultimately enter production of commercial volumes of the target compound.
Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, said: "This marks the first CDMO project to advance to Stage Two, and we are excited to continue working with a valued pharmaceutical partner on a high-impact therapeutic drug product. This milestone validates the versatility of our Botanical Synthesis platform to deliver scalable, cost-effective alternatives to traditional compound sourcing. Stage One success also reinforces our position as a trusted partner for pharma, nutrition, and nutraceutical players seeking next-generation plant-based solutions. We expect this achievement to accelerate additional CDMO opportunities as we help shape the future of therapeutics."
Dr. Zaki Rakib, Chairman and President of the CDMO Division, concluded: "Stage One carries the highest technical risk, requiring extensive AI-assisted research. Completing it successfully proves our platform can address a broad range of molecule families. Stage Two will focus on scaling biomass and refining compound concentration, and carries a much higher probability of success. Importantly, this project sharpened our analytical capabilities and validated our in-house AI tools, which will now support all future CDMO engagements."
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized. There is no assurance of future contracts. Readers are cautioned that additional contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251721
FAQ
What milestone did BioHarvest (BHST) achieve in its CDMO contract?
What is the next stage for BioHarvest's (BHST) CDMO project?
How does BioHarvest's Botanical Synthesis platform work for pharmaceutical compounds?
What impact does the Stage 1 completion have on BioHarvest's (BHST) future prospects?
